A Study to Evaluate Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in Major Depressive Disorder (TERPSIS STUDY) (H-50643)
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in Major Depressive Disorder (TERPSIS STUDY)
Is depression making you miss out?
If you are being treated for major depressive disorder (MDD) but still feel a lack or loss of interest in usually pleasurable activities, the TERPSIS Study, a clinical research study on an investigational medication for MDD, may be of interest to you.
The TERPSIS Study is researching a potential MDD therapy to improve symptoms of depression, and you may be able to participate.
Those who qualify will receive the investigational medication (or placebo), study-specific medical exams, and study-specific laboratory tests at no cost.
Participants in the TERPSIS Study must:
- Be 18 to 65 years of age
- Have a clinical diagnosis of MDD
- Be taking antidepressant medication(s) but still feeling a lack of interest in usually pleasurable activities.
Participants will receive study-related medical care and investigational study medication at no cost and may be eligible for compensation for time and travel.